title: Coronary risks after high-dose gamma-globulin in children with Kawasaki disease.
abstract: OBJECTIVE
  The goals of the present study were to develop a predictive coronary risk scoring system after intravenous gamma-globulin (IVGG) therapy of any dose for the different preparations currently used in the treatment of children with Kawasaki disease and to determine the predictive value of the system. The previously reported scoring systems were based on treatment with high-dose IVGG therapy at limited doses and were determined using investigative methods.
  
  
  METHODS
  Four hundred and fifty-one patients were randomized into one of three groups and received either i.v. polyethylene glycol-treated human immunoglobulin at a dose of either 200 (n = 147) or 400 mg/kg per day (n = 152) or freeze-dried sulfonated human immunoglobulin at 200 mg/kg per day (n = 152) for 5 consecutive days. We documented 31 cases of coronary abnormalities (CA). Univariate and multivariate logistic regression was performed using 49 clinical variables and the resulting predictive model was validated.
  
  
  RESULTS
  The duration of fever (odds (I day)/odds (- 5 days)= 0.158; 95% confidence interval (CI) 0.0385-0.648), hemoglobin (odds (Q1 = 10.3)/odds (Q3 = 11.6) = 3.97; 95% CI 1.92-8.20), IgG (odds (Q1 = 1,900)/odds (Q3=2,658)=2.72, 95% CI 1.18-6.25) and IgA (odds (Q1 =72)/odds (Q3= 160) = 0.415; 95% CI 0.253-0.680) levels after completion of gamma-globulin infusion were independent predictors. The model is quasi-cross validated and has acceptable sensitivity and selectivity. The estimated risk and observed occurrence of CA coincide.
  
  
  CONCLUSIONS
  Determinants of the risk of CA after IVGG therapy are a longer duration of fever, a lower IgG level, a higher IgA level and a lower hemoglobin level after IVGG infusion. This model is applicable for IVGG doses from 1 to 2 g/kg and for at least two different gamma-globulin preparations.
authors.affiliation: Department of Pediatrics, Keio University, Tokyo, Japan. morikawa@mc.med.keio.ac.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Morikawa
authors.forename: Y
authors.initials: Y
authors.lastname: Ohashi
authors.forename: K
authors.initials: K
authors.lastname: Harada
authors.forename: T
authors.initials: T
authors.lastname: Asai
authors.forename: S
authors.initials: S
authors.lastname: Okawa
authors.forename: M
authors.initials: M
authors.lastname: Nagashima
authors.forename: T
authors.initials: T
authors.lastname: Katoh
authors.forename: K
authors.initials: K
authors.lastname: Baba
authors.forename: K
authors.initials: K
authors.lastname: Furusho
authors.forename: M
authors.initials: M
authors.lastname: Okuni
authors.forename: M
authors.initials: M
authors.lastname: Osano
mesh_terms: D002648:Child; D003327:Coronary Disease / Q000209:etiology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D016015:Logistic Models; D009080:Mucocutaneous Lymph Node Syndrome / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D018570:Risk Assessment
chemical_list: D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous